Document is current
Any future updates will be listed below
-
Authors
Li, Peishun https://orcid.org/0000-0003-4200-0474
Ji, Boyang https://orcid.org/0000-0002-7269-4342
Luo, Hao
Sundh, Daniel
Lorentzon, Mattias
Nielsen, Jens https://orcid.org/0000-0002-9955-6003
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden
Knut och Alice Wallenbergs Stiftelse
IngaBritt och Arne Lundbergs Forskningsstiftelse
Svenska Forskningsrådet Formas
Sahlgrenska Universitetssjukhuset
- License Information
-
More Information
Article History
Received: 4 August 2021
Accepted: 6 October 2022
First Online: 19 October 2022
Competing interests
: The authors declare no competing interests. Prof Lorentzon has received lecture or consulting fees from Astellas, Gedeon Richter, Amgen, Lilly, UCB Pharma, Radius Health, Meda, GE-Lunar and Santax Medico/Hologic, all outside the herein presented work. BioGaia AB provided funding for the randomized controlled trial<sup>9</sup>, which the current report is partially based on. BioGaia AB did not have access to any metabolomics data, and has not participated in the analysis, interpretation or presentation of results of the present study.
